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A B S T R A C T
Purpose
Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis
(AL), but it is associated with a high risk of early mortality (EM). In a multicenter randomized comparison
against oral chemotherapy, autotransplantation was associated with 24% EM. We analyzed trends in
outcomes after autologous hematopoietic cell transplantation for AL in North America.
Patients and Methods
Between 1995 and 2012, 1,536 patients with AL who underwent autotransplantation at 134
centers were identified in the Center for International Blood and Marrow Transplant Research
database. EM and overall survival (OS) were analyzed in three time cohorts: 1995 to 2000 (n 
140), 2001 to 2006 (n  596), and 2007 to 2012 (n  800). Hematologic and renal responses and
factors associated with EM, relapse and/or progression, progression-free survival and OS were
analyzed in more recent subgroups from 2001 to 2006 (n  197) and from 2007 to 2012 (n  157).
Results
Mortality at 30 and 100 days progressively declined over successive time periods from 11% and 20%,
respectively, in 1995 to 2000 to 5% and 11%, respectively, in 2001 to 2006, and to 3% and 5%,
respectively, in 2007 to 2012. Correspondingly, 5-year OS improved from 55% in 1995 to 2000 to 61% in
2001 to 2006 and to 77% in 2007 to 2012. Hematologic response to transplantation improved in the latest
cohort. Renal response rate was 32%. Centers performing more than four AL transplantations per year had
superior survival outcomes. In the multivariable analysis, cardiac AL was associated with high EM and
inferior progression-free survival and OS. Autotransplantation in 2007 to 2012 and use of higher dosages of
melphalan were associated with a lowered relapse risk. A Karnofsky score less than 80 and creatinine levels
2 mg/m2 or greater were associated with worsened OS.
Conclusion
Post-transplantation survival in AL has improved, with a dramatic reduction in early post-
transplantation mortality and excellent 5-year survival. The risk-benefit ratio for autotransplantation
has changed, and randomized comparison with nontransplantation approaches is again warranted.
J Clin Oncol 33:3741-3749. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Light-chain amyloidosis (AL) is a multisystemic dis-
ease caused by a malignant plasma cell clone with
resultant insoluble fibrillar deposition.1 Amyloid fi-
brils derived from misfolded immunoglobulin light
chains cause direct organ toxicity leading to organ
failure and death. Current AL therapies focus on
eliminating the source of amyloid, that is, the plasma
cell clone, by using chemotherapy. However, che-
motherapy has minimal effect on preformed organ
amyloid; consequently, organ improvements lag be-
hind hematologic responses.2 After diagnosis, pa-
tients, particularly those with advanced cardiac AL,
are at increased risk for early death from progressive
heart failure and sudden death despite the use of
effective chemotherapy.3
The role of autologous hematopoietic cell
transplantation, or autotransplantation, in AL is
controversial. Single-center studies revealed good
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outcomes in terms of hematologic responses and organ
improvement.4-6 However, the prospective randomized clinical
trial reported in 2007 in which autotransplantation was compared
with oral melphalan and dexamethasone showed inferior survival
with autotransplantation.7 Inferior outcomes were related to high
early mortality (EM) of 24% in the transplantation arm and were
partly attributed to the inclusion of patients with severe cardiac
amyloidosis7 and possibly related to low-volume amyloid trans-
plantation centers.8 Since that study,7 use of cardiac biomarkers—
serum troponin T and N-terminal of brain natriuretic peptide
— has helped improve detection and risk stratification in patients
with cardiac AL.9 These refined selection criteria for autotrans-
plantation, along with improvements in supportive care of patients
in the peritransplantation period, have translated into a decrease in
the post-transplantation EM to less than 5% at large amyloid
centers in the United States.10,11 We hypothesized that outcomes of
autotransplantation among patients with AL have improved over
time. In addition, we wanted to test the utility of autotransplanta-
tion in AL in practice and to assess if center AL transplantation
experience affects outcomes. We undertook a retrospective study
using the Center for International Blood and Marrow Transplant
Research (CIBMTR) database to address these issues.
PATIENTS AND METHODS
Data Source
The CIBMTR is a prospectively maintained registry that collects
transplantation data from over 320 centers worldwide. Data are collected
at two levels: registration and research. The registration data include dis-
ease type, age, sex, date of diagnosis, graft type, conditioning regimen,
post-transplantation disease progression, survival, and cause of death, and
it includes all transplantations reported to the CIBMTR. More-detailed
clinical data are collected from a subgroup of registered patients selected
for research data by using a weighted randomization scheme. Both the
registration data and the research data are collected pretransplantation, at
100 days and 6 months post-transplantation, and annually thereafter until
death or last follow-up.
Patients
Included in this study were patients registered with the CIBMTR in
North America between 1995 and 2012 for an autotransplantation for AL
within 24 months of diagnosis. Data from these patients were analyzed in three
arbitrarily grouped cohorts based on the year of transplantation: 1995 to 2000,
2001 to 2006, and 2007 to 2012. Registration data set was used to assess survival
outcomes. Robust research data were available for a subgroup of 354 patients
who underwent transplantation between 2001 and 2012. This subgroup was
analyzed for hematologic and organ responses and in multivariable analyses.
Key characteristics and survival were compared between the registration set
and this subset to confirm that the subgroup was a random representative of
the data set (Appendix Table A1, online only, and Appendix Table A2, online
only). Data accuracy was established by means of physician review (by A.
D’Souza and P.H.) of discrepant data when present, and centers were con-
tacted if needed for additional review.
Definitions of Early Mortality, Response, and Center Effect
EM was defined as mortality from any cause after transplantation within
the defined time windows of 30 and 100 days. This differed from
transplantation-related mortality (TRM), which excluded patients who died as
a result of progressive AL or relapse. This avoided attribution bias wherein
mortality from organ amyloid in the post-transplantation period could have
been labeled as being caused by disease and, thus, causing an underestimation
of TRM. Use of EM ensured that the risk of post-transplantation death was not
underreported and that mortality in the post-transplantation period was ac-
curately described irrespective of attribution to disease versus treatment-
related causes.
The uniform system proposed at the 10th International Symposium
on Amyloidosis was used to define hematologic and renal response and
progressions.12 In 2012, new criteria were proposed to define hematologic
response and progression on the basis of free light-chain (FLC) analysis.3
Because FLC and cardiac biomarkers were collected only after 2008, we
were unable to apply the 2012 hematologic or cardiac response criteria to
our data set retrospectively. Among organ responses, only renal response is
reported in this analysis.
The association between amyloid transplantation volume and survival
was analyzed as center experience.8 Owing to a wide variability in the numbers
of transplantations performed by centers over the 18-year period of this study,
center effect was calculated by using the mean number of amyloid transplan-
tations performed per year over the 4 years13 between 2009 and 2012. Center
experience in transplantation for AL was considered a dichotomous variable.
After we preformed maximum likelihood testing using the various cut points
of two, three, four, five, and 10 amyloid transplantations per year, we estab-
lished that a minimum of four AL transplantations per year was an informative
divider for this analysis.
Statistical Analysis
Patient-, disease- and treatment-related factors were compared by using
the [CHI]2 test for categorical variables and the Kruskall-Wallis test for con-
tinuous variables. Outcomes analyzed included EM, relapse and/or progres-
sion, progression-free survival (PFS), and overall survival (OS). Estimates of
outcomes were reported as probabilities with 95% CIs. The probability of OS
was calculated with the Kaplan-Meier estimator, with the variance estimated
by using the Greenwood formula. Survival curves were compared with the
log-rank test. Multivariable analysis was performed by using the research data
subset (n  354) with a Cox proportional hazards model in which the trans-
plantation period cohort of 2001 to 2006 versus 2007 to 2012 was the main
effect. Other factors included age at transplantation, race, pretransplantation
Karnofsky performance score (KPS), hematopoietic cell transplantation–
comorbidity index (HCT-CI), serum creatinine level, serum albumin level,
bone marrow plasma cell burden, amyloid organ pattern, number of involved
organs, pretransplantation chemotherapy, time from diagnosis to transplan-
tation, melphalan dose in mg/m2 and center effect. The assumption of propor-
tional hazards was tested for each variable, and factors violating the
proportionality assumption were adjusted by stratification. Potential interac-
tions between the main effect and all other significant risk factors were tested.
All P values were two-sided, and P  0.05 was considered to indicate a
significant difference.
RESULTS
Patient-, Disease-, and Transplantation-
Related Variables
Table 1 displays available characteristics for the entire group
from 1995 to 2012 (n  1,536), and Table 2 shows data for the
subset with detailed level data from 2001 to 2012 (n  354). The
median age at transplantation was 56 years, with evidence of in-
creasing age at transplantation with successive time cohorts (Table
1). Most patients underwent transplantation within 6 months of
diagnosis. The underlying plasma cell clone was  in 72% of cases
(Table 2). The M-spike was nonquantifiable in 42% of patients;
when quantified, the median size was 0.6 g/dL. The distribution of
cardiac and renal involvement was similar between the groups. Few
patients had noncardiac, nonrenal organ involvement in this
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cohort, and renal involvement without cardiac involvement was
the most frequently observed pattern. We found no difference in
the 2001-to-2006 and 2007-to-2012 groups in terms of the number
of organs involved, and four or more organ were involved in 12%
and 11% patients, respectively. Most patients had no treatment
before transplantation, but more patients received treatment in
2007 to 2012 than in 2001 to 2006 (33% v 13%, P  .001). Mel-
phalan dosage was reduced most frequently in 2007 to 2012, with
64% of patients receiving less than 180 mg/m2 of melphalan con-
ditioning, and 34% received less than 140 mg/m2.
EM and Causes of Death in 1,536 Patients
Figure 1A shows EM for the three groups. Mortality at 30 and
100 days declined from 11% (95% CI, 7% to 17%) and 20% (95%
CI, 14% to 27%), respectively, for the 1995-to-2000 group to 5%
(95% CI, 4% to 7%) and 11% (95% CI, 8% to 13%) for the
2001-to-2006 group to 3% (95% CI, 2% to 4%) and 5% (95% CI,
4% to 7%) for the 2007-to-2012 group (P  .001). No difference
was seen in EM based on the time from diagnosis to transplanta-
tion. Rates were, at less than 6 months, 12% (95% CI, 8% to 17%);
at 6 to 12 months, 5 (95% CI, 1% to 11%); and 12 to 24 months, 8%
(95% CI, 2% to 18%). Causes of death reported within the first 100
days were attributed to amyloid and organ failure in most patients
(83%), followed by infection (8%), nonengraftment (3%), and
unknown causes (6%).
OS in 1,536 Patients
Median follow-up was 56 months (5 to 209 months) from the
time of diagnosis. One-, 3- and 5-year OS in successive cohorts im-
proved from 75% (95% CI, 65% to 82%), 64% (95% CI, 56% to 72%),
and 55% (95% CI, 46% to 63%), respectively, for 1995 to 2000 to 85%
(95% CI, 81% to 87%), 72% (95% CI, 68% to 75%), and 61% (95%
CI, 57% to 65%), respectively, for 2001 to 2006 and to 90% (95% CI,
88% to 92%), 83% (95% CI, 80% to 86%), and 77% (95% CI, 72 to
82%), respectively, for 2007 to 2012 (P  .001; Fig 1B).
We observed no difference in OS based on the time from diag-
nosis to transplantation. Rates were, at less than 6 months, 73% (95%
CI, 67% to 79%); at 6 to 12 months, 81% (95% CI, 71% to 89%); and
at 12 to 24 months, 81% (95% CI, 61% to 92%; P  0.22).
For patients with cardiac amyloidosis, 3-year OS improved from
62% (95% CI, 48% to 75%) in 2001 to 2006 to 67% (95% CI, 52% to
80%) in 2007 to 2012 (P  .59; Fig 2A). For those with renal and
without cardiac amyloidosis, 3-year OS improved from 78% (95% CI,
68% to 86%) in 2001 to 2006 to 89% (95% CI, 82% to 95%) in 2007 to
2012 (P  .03; Fig 2B).
Response Rates in the Subset of 354 Patients
A best hematologic response to transplantation was available in
89% and 97% of patients in the 2001-to-2006 and 2007-to-2012
groups, respectively. A renal response at any point after autotransplan-
tation was available in 70% and 78% of patients in 2001 to 2006 and
2007 to 2012, respectively. Table 3 shows a breakdown of hematologic
and renal responses that were observed in this cohort. The hemato-
logic response rate was higher in the 2007-to-2012 cohort than in the
2001-to-2006 cohort.
Center Effects in the Subset of 354 Patients
EM was worse among 81 centers that performed fewer than four
AL transplantations per year, that is, low volume, than in others. Their
mortality rate of 5% (95% CI, 3% to 7%) at 30 days and 7% (95% CI,
5% to 10%) at 100 days compared with 1% (95% CI, 0.4% to 3%) at 30
days and 3% (95% CI 2% to 6%) at 100 days for centers that
performed four or more AL transplantations a year, or high volume
(n  11; P  .01; Fig 2C). No statistically significant difference was
found for age, KPS, HCT-CI, cardiac amyloidosis, number of organs




Overall (N  1,536)1995-2000 (n  140) 2001-2006 (n  596) 2007-2012 (n  800)
No. of centers 50 93 104 134
Age at transplantation, years
Median age (range) 54 (31-71) 57 (23-78) 59 (26-77) 56 (23-78)
18-39 12 (9) 21 (4) 23 (3) 272 (18)
40-49 30 (21) 123 (21) 119 (15) 604 (39)
50-59 65 (46) 244 (41) 295 (37) 362 (24)
60-65 30 (21) 118 (20) 214 (27) 242 (16)
 66 3 (2) 90 (15) 149 (19) 56 (4)
Male sex 85 (61) 355 (60) 483 (60) 923 (60)
Karnofsky score  80 21 (15) 82 (14) 110 (14) 213 (14)
Time from diagnosis to transplant, months
 6 80 (57) 399 (67) 483 (60) 962 (63)
6-12 41 (29) 145 (24) 214 (27) 400 (26)
12-24 19 (14) 52 (9) 103 (13) 174 (11)
Median follow-up of survivors from diagnosis (range), months 146 (7-209) 97 (5-152) 33 (6-94) 56 (5-209)
Median follow-up of survivors from transplantation (range), months 142 (4-194) 93 (3-145) 25 (3-76) 49 (3-194)
Abbreviations: AL, light-chain amyloidosis; autoHCT, autologous hematopoietic cell transplantation; CIBMTR, Center for International Blood and Marrow Transplant
Research.
Autologous Transplantation in AL amyloidosis
www.jco.org © 2015 by American Society of Clinical Oncology 3743





2001-2006 (n  197) 2007-2012 (n  157)
No. of centers 51 41
Age at transplantation, years .05
Median age (range) 57 (31-75) 58 (26-74) .28
18-39 3 (2) 8 (5)
40-49 43 (22) 19 (12)
50-59 79 (40) 67 (43)
60-65 36 (18) 36 (23)
 66 36 (18) 27 (17)
Male sex 116 (59) 100 (64) .36
Race .12
White 169 (86) 134 (85)
African American 17 (9) 13 (8)
Other/unknown 11 (6) 10 (6)
Karnofsky score  80 31 (16) 20 (13) .38
HCT comorbidity score  .001
0 36 (18) 33 (21)
1-2 74 (38) 46 (29)
 3 19 (10) 63 (40)
Unknown 68 (35) 15 (10)
Disease Related
Involved serum free light chain (after year 2008) NE
No. evaluated NE 110
 — 79 (72)
 — 31 (28)
Serum monoclonal immunoglobulin at diagnosis, g/dL
No. evaluated 74 98
Nonquantifiable 25 (34) 48 (49)
Median when measured (range) 0.7 (0.0002-5.0) 0.5 (0.0004-6.3) .28
Bone marrow plasma cells, % .53
 10 136 (69) 114 (73)
 10 26 (13) 22 (14)
Unknown 35 (18) 21 (13)
Serum creatinine at any time pretransplantation, mg/dL .06
 2 158 (80) 118 (75)
 2 39 (2) 35 (22)
Unknown 0 4 (3)
Serum albumin at any time before pretransplantation, g/dL .003
 2.5 74 (38) 49 (31)
2.5-3 37 (19) 27 (17)
 3 72 (37) 80 (51)
Unknown 14 (7) 1 ( 1)
Organ Involvement
Organ or system
Cardiac 75 (38) 59 (38) .47
Renal 142 (72) 120 (76) .01
Hepatic 20 (10) 9 (6) .56
Autonomic nervous system 27 (14) 13 (8) .11
No. of organs involved .37
1 55 (28) 52 (33)
2 60 (30) 51 (32)
3 48 (24) 33 (21)
 4 23 (12) 18 (11)
Unknown 11 (6) 3 (2)
Type of organ involvement .28
Cardiac (cardiac  renal  others) 75 (38) 59 (38)
Predominant renal (renal  others) 85 (43) 77 (49)
Other 26 (13) 18 (11)
Unknown 11 (6) 3 (2)
(continued on following page)
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involved with amyloidosis, melphalan conditioning dosage, or pre-
transplantation chemotherapy between the high-volume and low-
volume centers (Appendix Table A3, online only). Both high- and
low-volume centers showed an improvement in reported EM in the
three time cohorts (P  .01; Fig 2D).
Multivariable Analysis in the Subset of 354 Patients
Table 4 shows results of the multivariable analysis. Adjusted
analysis showed no difference between the 2001-to-2006 cohort and
the 2007-to-2012 cohort for EM, PFS, or OS. The analysis for relapse
and/or progression was nonproportional, and the optimal cut point





2001-2006 (n  197) 2007-2012 (n  157)
Transplantation Related
CD34 cells infused,  106/kg 160 113 .01
Median (range) 4.8 (1.0-16.8) 4.0 (1.2-17.3)
Melphalan dose, mg/m2 .01
Median (range) 175 (86-241) 143 (86-219) .15
140 65 (33) 69 (44)
140-180 31 (16) 31 (20)
 180 86 (44) 54 (34)
Missing/outliers 15 (8) 3 (2)
Pretransplantation chemotherapy  .001
Untreated 167 (85) 105 (67)
Melphalan based 13 (7) 15 (10)
IMID based 12 (6) 22 (14)
Bortezomib based 0 15 (10)
Missing 5 (3) 0
Time from diagnosis to transplantation, months .92
 6 131 (66) 103 (66)
6-12 46 (23) 36 (23)
12-24 20 (10) 18 (11)
Median follow-up of survivors from diagnosis (range), months 89 (5-51) 56 (12-82)
Median follow-up of survivors from transplant (range), months 77 (3-145) 49 (7-75)
Abbreviations: HCT, hematopoietic cell transplantation; IMID, immunomodulatory drug; NE, nonevaluable.


















20 40 60 80 100
P < .001
 n 30 Days        100 Days       
1995-2000 140 11% (7% to 17%) 20% (14% to 27%)
2001-2006 596 5% (4% to 7%) 11% (8% to 13%)
2007-2012 800 3% (2% to 4%) 5% (4% to 7%)
 n      5-Year OS     
1995-2000 140 55% (46% to 63%)
2001-2006 596 61% (57% to 65%)


















1 2 3 4 5
P < .001
Fig 1. Probabilities of (A) early mortality and (B) overall survival (OS) in light-chain amyloidosis after transplantation for all three time cohorts.
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identified was 9 months after transplantation. During the initial pe-
riod, no difference occurred between the 2001-to-2006 and 2007-to-
2012 cohorts for relapse and/or progression. After 9 months, the
relapse and/or progression rate was lower in the 2007-to-2012 cohort.
The presence of cardiac involvement was associated with increased
EM (hazard ratio [HR], 3.5; 95% CI, 2 to 6.4; P  .001), worse PFS
(HR, 2.0; 95% CI, 1.7 to 3.0; P  .001), and OS (HR, 2.5; 95% CI, 1.6
to 3.9; P  .001).
DISCUSSION
We describe outcomes after autotransplantation in the largest cohort
of patients with AL reported to date. We make a number of clinically
important observations. First, impressive reduction in EM has been
achieved in recent years, and this is superior to the reported TRM of
24% from the only randomized clinical trial we know of in this set-
ting.7 Second, cardiac amyloid involvement remains the critical vari-
able associated with worse outcomes, with no improvement in
outcomes of patients with cardiac amyloidosis over time. Third, center
experience with AL transplantation is important in reducing EM.
Centers that perform four or more AL transplantations per year report
better results than those that do not. Fourth, 5-year survival in this
real-world experience of autotransplantation has improved to 77% in
the most recent cohort. This is comparable to data from specialized
single centers and superior to the transplant arm of the randomized
trial.7,14
Although established as an effective treatment modality in AL,
autotransplantation has been controversial, owing to inferior out-
comes reported in the prospective, randomized controlled, phase III
trial described in 2007.7 Further, more recently, combination chemo-
therapy using novel agents such as bortezomib with alkylators has
been shown to be associated with prompt and deep hematologic
responses in the upfront setting.15-18 Therefore, the role of autotrans-
plantation in AL has been further questioned. This is reflected in our
BA
   30 Days      100 Days     
< 4 AL HCTs per year 5% (3% to 7%) 7% (5% to 10%)









































































20 40 60 80 00108060402001
P = .01
         3-Year OS        
2007-2012 89% (82% to 95%)
2001-2006 78% (68% to 86%)
         3-Year OS        
2007-2012 67% (52% to 80%)
2001-2006 62% (48% to 75%)
 30 Days        100 Days       
1995-2000 10% (4% to 19%) 19% (11% to 30%)
2001-2006 7% (5% to 10%) 11% (8% to 14%)
2007-2012 2% (1% to 3%) 4% (2% to 6%)
Fig 2. Trends in (A) overall survival (OS) for cardiac light-chain amyloidosis (AL); (B) OS for renal, noncardiac AL; (C) early mortality (EM) based on center experience;
and (D) time trends in improvement in EM among centers.
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study; the number of transplantations performed in the US did not
rise as rapidly after 2007 as they did in the preceding years.
Despite similar proportion of patients with cardiac involvement,
transplantation after 2007 was associated with lower EM and superior
OS than the earlier time periods. Therefore, EM improvements ap-
peared to be multifactorial, representing improvements in supportive
care and a higher level of experience overall in caring for these patients
with complex conditions and not merely selection of fitter patients.
Among patients with a renal, noncardiac pattern of AL involvement,
outcomes improved significantly over time. However, for patients
with cardiac AL, we were unable to demonstrate a statistically signifi-
cant change in survival over time. A similar finding has been reported
by others with novel chemotherapies17,19,20 and highlights the impor-
tance of earlier diagnosis of AL disease and an unmet need for safer
and more effective therapies for patients with advanced cardiac amy-
loidosis, including antifibril therapies.
In our subset analyses of 354 patients, we were able to study
response rates and prognostic factors. The response rate at day 100 was
limited by missing data, particularly for the 2001-to-2006 group;
therefore, it is not shown. However, when we assessed best hemato-
logic response to transplantation, we noted more complete and partial
hematologic responses in 2007 to 2012 than in 2001 to 2006. More
patients received pretransplantation induction chemotherapy during
2007 to 2012, but melphalan conditioning doses were also lower in this
period than in others. Of interest, renal response rates were equivalent
in 2001 to 2006 and 2007 to 2012 at 31% and 32%, respectively; this
result is similar to renal response of 33% reported after chemother-
apy.21 However, fewer patients, less than 10%, in both groups had
progression of renal AL. This was much lower compared with renal
progression after chemotherapy, even among the 50% of patients who
have complete and partial hematologic responses.21
A number of pretransplantation factors have been shown to be
prognostic after autotransplantation for AL. Cardiac biomarkers us-
ing serum cardiac troponin T and N-terminal of brain natriuretic
peptide provide a simple clinical prognostication system of staging AL
amyloidosis,9 improving our ability to screen for patients with ad-
vanced cardiac amyloidosis who are at increased risk for post-
transplantation complications and EM. Other known risk factors
associated with transplantation mortality include performance status
and multiorgan involvement with amyloidosis.22,23 In addition, low-
ered melphalan conditioning intensity to adjust for risk has been





Response No. % No. % P
Best hematologic response .005
Complete response 60 30 58 37
Partial response 44 22 53 34
Stable disease 42 21 25 16
Progression 7 4 3 2
Nonevaluable 22 11 14 9
Missing 22 11 4 3
Best renal response .30
Response 61 31 51 32
Stable disease 48 24 47 30
Progression 7 4 10 6
Nonevaluable 22 11 14 9
Missing 59 30 35 22
Nonevaluable was noted for patients who died in the first 100 days after
transplantation.
Table 4. Multivariable Analysis of Outcomes
Effect No.
Hazard
Ratio 95% CI P
Early mortality 336
2001-2006 183 1.0
2007-2012 153 0.956 0.567 to 1.613 .87
Type of organ involvement  .001
Cardiac 128 1.000
Renal, noncardiac 152 0.285 0.156 to 0.518  .001
Other 42 0.268 0.096 to 0.752 .01
Missing 14 0.206 0.028 to 1.507 .12
Relapse and or progression 331
Early event, 0-9 months .02
2001-2006 178 1.000
2007-2012 153 1.440 0.561 to 3.700 .45
Late event,  9 months
2001-2006 145 1.000
2007-2012 119 0.321 0.137 to 0.753 .01
Pretransplantation chemotherapy
Untreated 259
Treated 72 0.545 0.239 to 1.245 .15
Melphalan dose, mg/m2 .001
 140 128 1.000
140-180 58 0.511 0.235 to 1.114 .09
 180 131 0.237 0.118 to 0.474  .001
Missing 14 0.487 0.116 to 2.049 .33
Progression-free survival 336
2001-2006 183 1.000
2007-2012 153 0.821 0.553 to 1.219 .33
Karnofsky score .001
 80 265 1.000
 80 49 2.41 1.556 to 3.749  .001
Missing 22 1.305 0.560 to 3.040 .54
Type of organ involvement .003
Cardiac 128 1.000
Renal, noncardiac 152 0.504 0.331 to 0.766 .001
Other 42 0.424 0.217 to 0.832 .013
Missing 14 0.531 0.189 to 1.492 .23
Overall survival 350†
2001-2006 197 1.000
2007-2012 153 0.703 0.460 to 1.075 .1
Karnofsky score .001
 80 278 1.000
 80 51 2.670 1.694 to 4.206  .001
Missing 21 1.644 0.696 to 3.882 .26
Pretransplantation serum creatinine
level, mg/dL
 2 276 1.000
 2 74 1.7000 1.072 to 2.697 .02
Type of organ involvement .001
Cardiac 131 1.000
Renal, noncardiac 161 0.402 0.255 to 0.632  .001
Other 44 0.444 0.218 to 0.905 .03
Missing 41 0.425 0.129 to 1.401 .16
Five patients were excluded because pretransplantation chemotherapy data
were not available.
†Four patients excluded because pretransplantation serum creatinine levels
were not available.
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associated with a reduced response rate.24 In this study, we confirm
that cardiac involvement, poor renal function, poor KPS less than
80, and use of melphalan conditioning less than 180 mg/m2 are
associated with worse outcomes. The HCT-CI is a transplantation-
specific prognostic variable that was described and validated in the
mid-2000s. Although we were able to calculate it many patients
using reported comorbidities, this variable was unavailable in the
pre-2008 patient set. A bone marrow plasma cell clone greater than
10% has been found to be associated with worse outcomes,25,26 but
this finding was not replicated in our study. Although pretrans-
plantation chemotherapy was not associated with improved out-
comes, most of the pretransplantation chemotherapy included
nonbortezomib-based approaches.
In addition to the superior hematologic responses noted previ-
ously, patients in the 2007-to-2012 cohort also had a lower risk of
relapse starting 9 months after transplantation. This was an interesting
finding because lower doses of melphalan conditioning, which was
more common in the 2007-to-2012 period that in others, was an
independent predictor of relapse. Post-transplantation consolidation
with bortezomib has been associated with deepening of response
rates.27 In our analysis, only 38 patients received any post-
transplantation consolidation, and further analyses could not be per-
formed because of low numbers.
The best results for autotransplantation in AL have been reported
from specialized, high-volume centers in contrast to the multicenter,
randomized trial experience. It has been proposed that center experi-
ence in treating patients with AL is important, with low-volume cen-
ters having higher EM rates.8 Indeed, in our cohort, transplantation
centers performing fewer than four AL transplantations per year had
higher EM rates than those of centers performing four or more
transplantations. Lack of differences in the patient, organ, or
chemotherapy-related factors between high- and low-volume centers
led us to believe that high-volume centers do not necessarily select
fitter patients for transplantation. Rather, they may be more experi-
enced in supporting and treating these patients in the early post-
transplantation period. However, owing to the small numbers in the
subset analysis, our analysis was not powered to show significant
differences in outcomes on the basis of center volume in the multivari-
able analysis after other factors were adjusted.
Our study had a number of limitations inherent to its retrospec-
tive nature and the long interval under study. Amyloidosis manage-
ment is a dynamic field, and, during study inclusion, criteria for
response and organ involvement changed twice.12,28 Variability in
reporting by centers and the introduction of markers such as FLC,
cardiac biomarkers, and HCT-CI at various points during this period
were other issues inherent to the interval under study. Data regarding
FLC and cardiac biomarkers were not collected in our database after
2008, but serial FLC or cardiac biomarkers were reported for too few
patients to adequately define amyloid stage29 or response by using the
2012 criteria described by Palladini et al.28 Another limitation of our
study was our inability to stratify the severity of cardiac involvement
because cardiac biomarker information was not uniformly reported.
Therefore, although percentages of patients reported with cardiac
involvement were similar between the 2001-to-2006 and 2007-to-
2012 periods, we do not know if cardiac stage was similar between
these cohorts. Finally, our data were limited to individuals undergoing
transplantation, who are inherently a selected group of better-risk
patients.30
Although our study does not replace a controlled, transplantation-
versus-nontransplantation trial, it is reassuring to see that excellent
outcomes of autotransplantation previously reported from large sin-
gle centers were replicated in practice capturing most AL transplanta-
tions in the US. With the availability of novel plasma cell–directed
agents such as bortezomib, we propose that it is time to reconsider a
multi-institutional study to compare transplantation, perhaps limited
to high-volume centers, versus novel nontransplantation therapy.
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Appendix
Table A1. Subgroup Versus Cohort Comparison for Key Variables and Overall Survival
Variable Research Data Set (n  354) Entire Cohort (N  1,356) P
Age at transplantation, years
Median age (range) 57 (26-75) 58 (23-78) .40
18-39 11 (3) 44 (3)
40-49 62 (18) 242 (17)
50-59 146 (41) 539 (39)
60-65 72 (20) 332 (24)
 66 63 (18) 239 (17)
Sex .73
Male 216 (61) 838 (60)
Female 138 (39) 558 (40)
Country .08
United States 329 (93) 1,330 (95)
Canada 25 (7) 66 (5)
Race .88
White 303 (86) 1,188 (85)
African American 30 (8) 112 (8)
Others 12 (3) 49 (4)
Missing 9 (3) 47 (3)
Karnofsky score .02
80-100 278 (79) 1,031 (74)
 80 51 (14) 192 (14)
Missing 25 (7) 173 (12)
Time from diagnosis to transplantation, months .56
 6 234 (66) 882 (63)
6-12 82 (23) 359 (26)
12-24 38 (11) 155 (11)
Median follow-up of survivors (range), months 61 (3-145) 47 (3-145)
P for nonmissing groups  .93.
Table A2. Subgroup Versus Cohort Comparison for Early Mortality and Overall Survival
Research Data Set (n  354) Entire Cohort (N  1,396)
Outcome Probability (%) 95% CI Probability (%) 95% CI
Early mortality
1 month 94 91 to 96 96 95 to 97
100 day 90 86 to 93 93 91 to 94
Overall survival, years
1 83 79 to 87 88 86 to 89
3 76 71 to 80 77 75 to 80
5 70 64 to 75 68 65 to 71
NOTE. Log rank test P  .94.
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Table A3. Comparison of Key Variables Between High- and Low-Volume Light-Chain Amyloidosis Transplantation Centers
Center Experience, No. of Transplantations
 4 (n  91)  4 (n  66)
Variable No. % No. % P
Age at transplantation, years .60
18-39 3 3 5 8
40-49 13 14 6 9
50-59 40 44 27 41
60-65 19 21 17 26
 66 16 18 11 17
Karnofsky score .68
80-100 71 78 52 79
 80 13 14 7 11
Missing 7 8 7 11
Time from diagnosis to transplantation, months .49
 6 63 69 40 61
6-12 18 20 18 27
12-24 10 11 8 12
Cardiac involvement .24
Yes 37 41 22 33
No 32 35 32 48
Missing 22 24 12 18
Renal involvement .65
Yes 68 75 52 79
No 11 12 5 8
Missing 12 13 9 14
Organ involvement .13
0 1 1 2 3
1 29 32 23 35
2 36 40 15 23
3 18 20 15 23
4 7 8 11 17
Hematopoietic cell transplantation–comorbidity index .15
0 25 27 8 12
1 10 11 9 14
2 13 14 14 21
3 13 14 7 11
4 24 26 19 29
Missing 6 7 9 14
Melphalan dose, mg/m2 .20
 140 35 38 34 52
140-180 18 20 13 20
 180 37 41 17 26
Missing 1 1 2 3
Chemotherapy .09
No chemotherapy 65 71 40 61
Melphalan based 6 7 9 14
Thalidomide based 2 2 7 11
Lenalidomide based 9 10 4 6
Bortezomib based 9 10 6 9
NOTE. Center experience was measured by the mean number of light-chain transplantations performed at centers between 2009 and 2012. High volume was four
or more transplantations per year, and low volume was four or fewer transplantations per year.
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